DOCSLIB.ORG

|||||||IIII US005607691A United States Patent (19) 11 Patent Number: 5,607,691 Hale Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
|||||||IIII US005607691A United States Patent (19) 11 Patent Number: 5,607,691 Hale Et Al |||||||IIII US005607691A United States Patent (19) 11 Patent Number: 5,607,691 Hale et al. (45) Date of Patent: Mar. 4, 1997 54) COMPOSITIONS AND METHODS FOR 0559625 9/1993 European Pat. Off. ...... CO7C 229/22 ENHANCED DRUG DELIVERY 880 1615 3/1988 WIPO .......................... CO7C 103/30 9008128 7/1990 WIPO : 75) Inventors: Ron L. Hale, Woodside; Amy Lu, Los 9106556 5/1991 WIPO ............................ COTH 21100 9113631 '9/1991 WIPO ............................ A61K 39/00 Altos; Dennis Solas, San Francisco; 9114696 10/1991 WIPO ............................ CO7H 17/00 Harold E. Selick, Belmont; Kevin R. 9115259 10/1991 WIPO .............................. A61N 1/30 Oldenburg, Fremont; Alejandro C. 92/08459 5/1992 WIPO Zafaroni, Atherton, all of Calif. 92.17180 10/1992 WIPO .......................... A61K 3/505 92/22530 12/1992 WIPO. (73) Assignee: Affymax Technologies N.V., Middlesex, 93.07883 4/1993 WIPO ............................ A61K 31/70 England 93.17713 9/1993 WIPO ............................ A61K 47/48 OTHER PUBLICATIONS (21) Appl. No.: 449,188 Bodor, et al. Int. J. Pharm, 35(1-2) 47-59 1987 Improved 22) Filed: May 24, 1995 Delivery Through Biological Membranes. Pratt et al., 1990, Principles of drug action: The basis of Related U.S. Application Data pharmacology 203-227 Principles of drug action: The basis of pharmacology. (63) Continuation of Ser. No. 164,293, Dec. 9, 1993, abandoned, which is a continuation-in-part of Ser. No. 77,296, Jun. 14, Russell-Jones et al., 1988, Proceed Intern. Symp. Control. 1993, abandoned, which is a continuation-in-part of Ser. No. Rel. Bioact. Mater. 85: 142-143 Vitamin B12: A novel 898,219, Jun. 12, 1992, abandoned, and a continuation-in carrier for orally presented antigens. part of Ser. No. 9,463, Jan. 27, 1993, abandoned. Bodde et al., 1989, Biochemical Society 17 (3): 197-199 (51) Int. Cl." ........................... A61K 9/70; A61K 31/00 Transdermal peptide delivery. Sanderson et al., 1989, J. of Pharm. Sci. 78 (5): 361-364. 52 U.S. Cl. ................................. 424/449; 604/20; 514/1; Iontophoretic delivery of nonpeptide drugs: Formulation 514/2; 514/26; 514/183; 514/169; 514/553; optimization for maximum skin permeability. 514/556 Harris, Physical Medicine Library vol. IV, Therapeutic elec (58) Field of Search .............................. 424/22, 448, 449, tricity and ultraviolet radiation, pp. 146-149. 424/485, 486; 604/20; 514/1, 2, 26, 169, Foder et al., 1991, Science 251: 767-773 Light-Directed, 183,553,556 spatially addressable parallel chemical synthesis. Bioworld 29 Jan 92, 3 (20): p. 1 FDA approves Elan's (56) References Cited nicotine patch. U.S. PATENT DOCUMENTS Chien et al., 1989, J. Pharm. Sci. 78 (5): 376-383 Direct current iontophoretic transdermal delivery of peptide and 3,472,931 10/1969 Stoughton ............................... 424/180 protein drugs. 4,006,218 2/1977 Sipos ......................................... 424/54 4,144,328 3/1979 Vainshtein et al. ... 424/180 Srinivasan et al., 1989, J. of Pharm. Sci. 78(5): 370-375 4,195,172 3/1980 Falkowski et al. ................... 536/17 R Transdermal iontophoretic drug delivery : Mechanistic 4,294,958 10/1981 Falkowski et al. ....................... 536/17 analysis and application to polypeptide delivery. 4,427,660 1/1984 Schiffman et al. ..................... 424/177 West, Textbook of Biochemistry, Ch. 6: 169-170 Lipids. 4,454,065 6/1984 Gilvarget al. ...... ... 260/12 R Chien et al., 5 May 1989, J. Pharm. Sci. 78 (5): 353–354 4,588,580 5/1986 Gale et al. ................................ 424/21 Iontophoretic (transdermal) delivery of drugs: Overview of 4,645,502 2/1987 Gale et al. ................................ 604/89 historical development. 4,727,151 2/1988 Bodor .......... ... 546/174 Fix et al., 1986, The American Physiological Society: 4,788,062 11/1988 Gale et al. ...... ... 424/449 G332-G340 Acylccarnitines: drug absorption-enhancing 4,816,258 3/1989 Nedberg et al. ........................ 424/448 4,846,826 7/1989 Shaw et al. ..... 604/890. agents in the gastrointestinal tract. 4,900,555 2/1990 Cheng et al. ... ... 424/449 Banga et al., 1988, J. Controlled Release 7: 1-24 Ionto 4,904,475 2/1990 Gale et al. .............................. 424/449 phoretic delivery of drugs: Fundamentals, developments and 4,908,027 3/1990 Enscore et al. ...................... 604/890.1 biomedical applications. 4,927,408 5/1990 Haak et al. ............................... 604/20 Bernstein, 92, Bioworld 3 (105): p.1 Patch developers 4,963,367 10/1990 Ecanow ....... 424/485 extinguish suits. 4,978,337 12/1990 Theeuwes ................................. 604/85 5,011,686 4/1991 Pang............ ... 424/94.1 (List continued on next page.) 5,013,653 5/1991 Huston et al. .. ... 435/69.7 5,028,435 7/1991 Katz et al. ...... ... 424/484 Primary Examiner-Neil S. Levy 5,053,227 10/1991 Chiang et al. ... 424/484 Attorney, Agent, or Firm-Lauren L. Stevens 5,149,539 9/1992 Ledger et al. ...... ... 424/449 5,219,564 6/1993 Zalipsky et al. .... 424/78.17 (57) ABSTRACT 5,223,261 6/1993 Nelson et al. ... ... 424/443 The present invention relates to methods of delivering 5,246,967 9/1993 Zezza ...................................... 514/547 pharmaceutical agents across membranes, including the skin 5,270,472 12/1993 Taglialatela et al. ................... 560/251 layer or mucosal membranes of a patient. A pharmaceutical FOREIGN PATENT DOCUMENTS agent is covalently bonded to a chemical modifier, via a 0031722 7/1981 European Pat. Off. ........ COTH 17/08 physiologically cleavable bond, such that the membrane 0331391 9/1989 European Pat. Off. ....... A61K 45/00 transport and delivery of the agent is enhanced. 0351173 1/1990 European Pat. Off. ........ COTH 17/08 O385610 9/1990 European Pat. Off. ... A61K 39/295 5 Claims, No Drawings 5,607,691 Page 2 OTHER PUBLICATIONS Bodor et al., 18 Sep. 1992, Science 257: 1698–1700 A Behl et al., 1989, J. of Pharm. Sci. 78 (5): 355-360 Ionto strategy for delivering peptides into the central nervous phoretic drug delivery: Effects of physicochemical factors system by sequential metabolism. on the skin uptake of nonpeptide drugs. Benet et al., Pharmacokinetics: The dynamics of drug Jacobson et al., 1986, Mol. Pharmacol. 29: 126-133 A absorption, Distributuion, and elimination. Ch. 1: 3-10 fuctionalized congener approach to adenosine receptor Pharmacokinetics: The dynamics of drug absorption, distri antogonists: Amino Acid conjugates of 1,3-Dipropylxan bution, and elimination. thine. Phipps et al., 1989, J. of Pharm. Sci. 78 (5): 365-369 Iontophoretic delivery of model inorganic and drug ions. Jacobson et al., 1987, J. Med. Chem. 30: 1529-1532 Binary Ames et al., Feb. 1973, Proc. Natl. Acad. Sci., USA 70(2): Drugs: Conjugates of purines and a peptide that binds to 456-458 Illicit Transport: The Oligopeptide Permease. both adenosine and substance P receptors. 5,607,691 1. 2 COMPOSITIONS AND METHODS FOR dermal pharmaceutical agent delivery systems rely upon ENHANCED DRUG DELVERY pharmaceutical agents that are absorbed when admixed with inert carriers. See Cooper et al. (1987) “Penetration Enhanc This is a Continuation of application Ser. No. 08/164, ers', in Transdermal Delivery of Drugs, Vol. II, Kyodonieus 293, filed Dec. 9, 1993 now abandoned, which is a continu et al., Eds., CRC Press, Boca Raton, Fla. Few pharmaceu ation-in-part of application Ser. No. 08/077,296, filed Jun. tical agents fit this profile and those which do are not always 14, 1993 which is a continuation-in-part of applications Ser. predictably absorbed. Various forms of chemical enhancers, Nos. 07/898,219, filed Jun. 12, 1992 now abandoned, and such as those enhancing lipophilicity, have been developed 08/009,463, filed Jan. 27, 1993 now abandoned. Each of the to improve transdermal transport when physically mixed above identified applications are incorporated herein by 10 with certain therapeutic agents and provide more predictable reference for all purposes. absorption. See for example, U.S. Pat. Nos. 4,645,502; 4,788,062; 4,816,258; 4,900,555; 3,472,931; 4,006,218; and BACKGROUND OF THE INVENTION 5,053,227. Carriers have also been coupled to pharmaceu tical agents to enhance intracellular transport. See Ames et The present invention relates generally to methods for 15 al. (1973) Proc. Natl. Acad. Sci. USA, 70:456-458 and improving the transport and delivery of pharmaceutical (1988) Proc. Int. Symp. Cont. Rel. Bioact. Mater, 15:142. agents across membranes. More particularly, the invention Electric gradients also have been used to enhance trans relates to methods for enhancing the transport and delivery dermal pharmaceutical agent delivery. See Chien et al. of pharmaceutical agents through the addition of one or (1989) Journal of Pharmaceutical Sciences, 78(5):353–354 more chemical modifiers to the pharmaceutical agent. 20 and Banga et al. (1988) J. Controlled Release, 7:1-14. This The therapeutic efficacy of pharmaceutical or therapeutic technique, known as iontophoresis, uses an electric field to agents relies on the delivery of adequate doses of a phar enhance the rate of delivery of ionized pharmaceutical maceutical agent to the site of action. Many modes of agents through the skin. Typically, devices are used which delivery have been developed, including, for example, hold a pharmaceutical agent in a reservoir near the skin, enteral (oral), parenteral (intramuscular, intravenous, sub 25 generate an electric field surrounding the pharmaceutical cutaneous), and topical administration. In most instances the agent-dermal interface, and drive the agent through the skin. administration system is chosen for reliable dosage delivery For iontophoretic delivery, the drug molecules must be in and convenience. an ionized state with either a positive or negative charge. Typically, parenteral administration is the most reliable Nonionic drugs may also be delivered iontophoretically means of delivering a pharmaceutical to a patient. See, 30 provided that a charge can be induced on them, for example, Goodman et al., Goodman and Gilman's Pharmacological by adsorption of drug onto an ionic carrier or entrapment in Basis of Therapeutics, Pergamon Press, Elmsford, N.Y.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Escharotomy Incisions 17
    Emergency War Surgery Second United States Revision of The Emergency War Surgery NATO Handbook Thomas E. Bowen, M.D. Editor BG, MC, U.S. Army Ronald Bellamy, M.D. Co-Editor COL, MC, U.S. Army United States Department of Defense United States Government Printing Office Washington, D.C. 1988 Peer Review Status: Internally Peer Reviewed Creation Date: Unknown Last Revision Date: 1988 Contents Foreword Preface Prologue Acknowledgments Chapter I. General Considerations of Forward Surgery Part I. Types of Wounds and Injuries II. Missile-Caused Wounds III. Burn Injury IV. Cold Injury V. Blast Injuries VI. Chemical Injury VII. Mass Casualties in Thermonuclear Warfare VIII. Multiple Injuries Part II. Response of the Body to Wounding IX. Shock and Resuscitation X. Compensatory and Pathophysiological Responses to Trauma XI. Infection Part III. General Considerations of Wound Management XII. Sorting of Casualties XIII. Aeromedical Evacuation XIV. War Surgery Within the Division XV. Anesthesia and Analgesia XVI. Wounds and Injuries of the Soft Tissues XVII. Crush Injury XVIII. Vascular Injuries XIX. Wounds and Injuries of Bones and Joints XX. Wounds and Injuries of Peripheral Nerves XXI. Amputations Part IV. Regional Wounds and Injuries XXII. Craniocerebral Injury XXIII. Maxillofacial Wounds and Injuries XXIV. Wounds and Injuries of the Eye XXV. Laser Injury of the Eye XXVI. Wounds and Injuries of the Ear XXVII. Wounds and Injuries of the Neck XXVIII. Wounds and Injuries of the Chest XXIX. Wounds of the Abdomen XXX. Reoperative Abdominal Surgery XXXI. Wounds and Injuries of the Genitourinary Tract XXXII. Wounds and Injuries of the Hand XXXIII. Wounds and Injuries of the Spinal Column and Cord Appendixes A.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Nomination Background: 1-Butyl-3-Methylimidazolium Chloride
    Ionic Liquids 1-Butyl-3-methylimidazolium Chloride (CAS No. 79917-90-1) 1-Butyl-1-methylpyrrolidinium Chloride (CAS No. 479500-35-1) N-Butylpyridinium Chloride (CAS No. 1124-64-7) Review of Toxicological Literature May 2004 Ionic Liquids 1-Butyl-3-methylimidazolium Chloride (CAS No. 79917-90-1) 1-Butyl-1-methylpyrrolidinium Chloride (CAS No. 479500-35-1) N-Butylpyridinium Chloride (CAS No. 1124-64-7) Review of Toxicological Literature Prepared for National Toxicology Program (NTP) National Institute of Environmental Health Sciences (NIEHS) National Institutes of Health U.S Department of Health and Human Services Contract No. N01-ES-35515 Project Officer: Scott A. Masten, Ph.D. NTP/NIEHS Research Triangle Park, North Carolina Prepared by Integrated Laboratory Systems, Inc. Research Triangle Park, North Carolina May 2004 Toxicological Summary for Ionic Liquids 05/2004 Abstract Ionic liquids are salts of organic cations with melting points generally below 100 °C and are being widely investigated as replacements for volatile organic solvents in industrial and laboratory processes because they are thought to be "environmentally benign." Although some efforts have begun to study their potential for ecotoxicity, limited vertebrate or genetic toxicity testing has been done. Three ionic liquids, 1-butyl-3-methylimidazolium chloride ([bmim]Cl), 1-butyl-1-methylpyrrolidinium chloride ([bmpy]Cl), and N-butylpyridinium chloride ([NBuPy]Cl), were nominated to the National Toxicology Program (NTP) for toxicological testing based on their widespread interest as possible alternatives to organic solvents. These chlorides are representative of the three most common cation classes of ionic liquids being investigated: imidazolium, pyridinium, and pyrrolidinium. The chlorides, soluble in water and polar organic liquids, are generally prepared from approximately equimolar amounts of the appropriately substituted heterocyclic compound and butyl chloride, often under both heat and pressure.
    [Show full text]
  • Trigonelline [535-83-1]
    Trigonelline [535-83-1] Review of Toxicological Literature Prepared for Errol Zeiger, Ph.D. National Institute of Environmental Health Sciences P.O. Box 12233 Research Triangle Park, North Carolina 27709 Contract No. N01-ES-65402 Submitted by Raymond Tice, Ph.D. Integrated Laboratory Systems P.O. Box 13501 Research Triangle Park, North Carolina 27709 December 1997 EXECUTIVE SUMMARY The nomination of trigonelline for testing is based on its frequent occurrence in foods and the lack of carcinogenicity data. Trigonelline is a plant hormone which is claimed to have anticarcinogenic, antimigraine, antiseptic, hypocholesterolemic, and hypoglycemic activities. It may also act as a brain sedative. Trigonelline is widely distributed in plants within the subclass Dicotyledonae. It is also found in some species of Arthropods, Bryozoans, Cnidarians, Coelenterates, Crustaceans, Echinoderms, marine Poriferans, Molluscs, marine fishes, and mammals. Oral preparations (prepared by hot water extraction) of fenugreek, a plant which contains trigonelline, are thought to have antipyretic and antidiarrheal properties and are claimed to strengthen nails and revitalize hair. Fenugreek is also used in the preparation of imitation maple syrup and culinary spices other than curry. Another plant containing trigonelline is tung-kua-jen, which is prepared by hot water extraction and taken orally; it is used as a diuretic and antitussive. Trigonelline is a metabolite of niacin, which is used as a hypocholesterolemic and antihyperlipidemic. For medicinal purposes, niacin is taken orally in tablet form. Human exposure to trigonelline occurs when trigonelline-containing plants are consumed in the diet. Common foods containing trigonelline include barley, cantaloupe, corn, onions, peas, soybeans, and tomatoes. Exposure also occurs from herbel remedies, drinking coffee, and from eating fish, mussels, or crustaceans containing trigonelline.
    [Show full text]
  • L:\0901 with Peru\0901PHARMAPPX.Wpd
    Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACODAZOLE 79152-85-5 ABLUKAST 96566-25-5 ACOLBIFENE 182167-02-8 ABRINEURIN 178535-93-8 ACONIAZIDE 13410-86-1 ABUNIDAZOLE 91017-58-2 ACOTIAMIDE 185106-16-5 ACADESINE 2627-69-2 ACOXATRINE 748-44-7 ACAMPROSATE 77337-76-9 ACREOZAST 123548-56-1 ACAPRAZINE 55485-20-6
    [Show full text]
  • Abstract Acute Emetic Responses to Seven Cancer Chemotherapeutic
    Emesis Induced by Cancer Chemotherapeutic Agents in the Suncus Murinus: A New Experimental Model Norio MATSUKI, Shinya UENO, Takahide KAJI, Akane ISHIHARA, Chao-Hsiung WANG k and Hiroshi SAITO Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, University of Tokyo, Tokyo 113, Japan Chia-nan Junior College of Pharmacy, Tainan Hsien, Taiwan Accepted September 1, 1988 Abstract Acute emetic responses to seven cancer chemotherapeutic agents (adriamycin, bleomycin, cisplatin, cyclophosphamide, 5-fluorouracil, methotrexate, mitomycin C) were studied in the Suncus murinus. Intravenous injection of the drugs caused vomiting with various latency. Cisplatin-induced emesis was prevented by the pretreatment with metoclopramide or chlorpromazine but not with domperidone. These results indicate that the Suncus murinus is a useful animal for testing emetic activities of cancer chemotherapeutics and antiemetic activities of prophylactic drugs. Nausea and vomiting, although rarely life threatening, are painful side effects for the patients who receive cancer chemotherapy (1). However, developments of less emetic chemotherapeutic agents and antiemetic drugs are difficult because only a few mammals vomit in response to emetic drugs. The smallest mammal currently available for these purposes is the ferret (2,3), but its body weight is more than 1 kg. If we could use smaller mammals, it would be easier to test various agents for emetic and antiemetic activities. Recently we have shown that the Suncus murinus (house musk shrew), a species of insectivora, vomit in response to various emetic drugs (4) or motion stimulus (5). However, it is not known whether cancer chemotherapeutics induce emesis in the suncus. In the present study emetic response to several chemotherapeutics were investigated in the suncus for its use as a new animal model for emesis testing.
    [Show full text]
  • A Study of the Non-Caffeine Nitrogenous Compounds of Coffee
    . A STUDY OF THE NON-CAFFEINE NITROGENOUS COMPOUNDS OF COFFEE Dissertation Presented in Partial Fulfillment of theaRequirements for the Degree Doctor of Philosophy in the Graduate School of the Ohio State University By GERALD EMERSON UNDERWOOD, B. S., M. Sc. The Ohio £>tate University 1951 The author wishes to express his gratitude to his advisor, Professor F. E. Deatherage, under whose guidance this work was conducted, and to the Nestle Company for establishment of the Fellowship which made the project possible. 1 TABLE OF CONTENTS Page Introduction.......................................... 1 Literature Review ............................... 4 Experimentation....................................... 7 I. Study of proteins present in green coffee...... 7 Solubility classes of coffee proteins...... 8 Isolation iof water-soluble protein......... 11 Isoelectric point of water-soluble protein.. 13 Estimation of £roteolytic enzymes.......... 16 II. Fractionation of nitrogen compounds present in coffee on basis of solubility........ 22 Fractionation of green coffee.;. .. ...........22 Fractionation of roasted coffee....... 29 III. Study of amino acids present in coffee.... 33 Qualitative identification of amino acids... 33 Quantitative estimation of amino acids.......37 IV. Use of an ion exchange resin for hydrolysis of proteins.................................... 58 Hydrolysis of casein............... 60 Hydrolysis of water-soluble coffee protein.. 66 Discussion of Results.................................. 72 Summary.................. 79 Bibliography.......................................... 80 Autobiography......................................... 84 ii A STUDY OF THE NON-CAFFEINE NITROGENOUS COMPOUNDS IN COFFEE INTRODUCTION Coffee 1b tine name given to the seed of a small evergreen tree which is cultivated in tropical countries. The plant belongs to the genus Goffea, order Rublaoeae. The raw coffee seeds or "beans’1 are roasted by heating with hot combustion gases in rotating cylinders.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Study of the Active Ingredients and Mechanism of Sparganii Rhizoma In
    www.nature.com/scientificreports OPEN Study of the active ingredients and mechanism of Sparganii rhizoma in gastric cancer based on HPLC‑Q‑TOF–MS/MS and network pharmacology Xiaona Lu1,2,3, Yawei Zheng2,3, Fang Wen2, Wenjie Huang2, Xiaoxue Chen2, Shuai Ruan2, Suping Gu2, Yue Hu1,2, Yuhao Teng1,2 & Peng Shu1,2* Sparganii rhizoma (SL) has potential therapeutic efects on gastric cancer (GC), but its main active ingredients and possible anticancer mechanism are still unclear. In this study, we used HPLC‑Q‑TOF– MS/MS to comprehensively analyse the chemical components of the aqueous extract of SL. On this basis, a network pharmacology method incorporating target prediction, gene function annotation, and molecular docking was performed to analyse the identifed compounds, thereby determining the main active ingredients and hub genes of SL in the treatment of GC. Finally, the mRNA and protein expression levels of the hub genes of GC patients were further analysed by the Oncomine, GEPIA, and HPA databases. A total of 41 compounds were identifed from the aqueous extract of SL. Through network analysis, we identifed seven main active ingredients and ten hub genes: acacetin, sanleng acid, ferulic acid, methyl 3,6‑dihydroxy‑2‑[(2‑hydroxyphenyl) ethynyl]benzoate, cafeic acid, adenine nucleoside, azelaic acid and PIK3R1, PIK3CA, SRC, MAPK1, AKT1, HSP90AA1, HRAS, STAT3, FYN, and RHOA. The results indicated that SL might play a role in GC treatment by controlling the PI3K‑ Akt and other signalling pathways to regulate biological processes such as proliferation, apoptosis, migration, and angiogenesis in tumour cells. In conclusion, this study used HPLC‑Q‑TOF–MS/MS combined with a network pharmacology approach to provide an essential reference for identifying the chemical components of SL and its mechanism of action in the treatment of GC.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2010) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2010) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify
    List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify, abnormal basal ganglia function, abuse of medicines, Aceperone, Acepromazine, Aceprometazine, Acetildenafil, Aceto phenazine, Acetoxy Dipt, Acetyl morphone, Acetyl propionyl morphine, Acetyl psilocin, Activation syndrome, acute anxiety, acute hypertension, acute panic attacks, Adderall, Addictions to drugs, Addictions to medicines, Addictions to substances, Adrenorphin, Adverse effects of psychoactive drugs, adverse reactions to medicines, aggression, aggressive, aggressiveness, agitated depression, Agitation and restlessness, Aildenafil, Akuammine, alcohol abuse, alcohol addiction, alcohol withdrawl, alcohol-related brain damage, alcohol- related liver damage, alcohol mix with medicines for adverse reaction, Alcoholism, Alfetamine, Alimemazine, Alizapride, Alkyl nitrites, allergic breathing reactions to meds, choking to anaphallectic shock, & death; allergic skin reactions to meds, rash, itchyness, hives, welts, etc, Alletorphine, Almorexant, Alnespirone, Alpha Ethyltryptamine, Alpha Neoendorphin, alterations in brain hormones, alterations in mental status, altered consciousness, altered mind, Altoqualine, Alvimopan, Ambien, Amidephrine, Amidorphin, Amiflamine, Amisulpride, Amphetamines, Amyl nitrite, Anafranil, Analeptic, Anastrozole, Anazocine, Anilopam, Antabuse, anti anxiety meds, anti dopaminergic activity, anti seizure meds, Anti convulsants, Anti depressants, Anti emetics, Anti histamines, anti manic meds, anti parkinsonics, Anti psychotics, Anxiety disorders,
    [Show full text]